Interventions of Interest: enzalutamide (Xtandi®, Astellas and Medivation) abiraterone acetate (Zytiga®, Janssen) apalutamide (Erleada™, Janssen). October 2018 Review ICER developed a report on anti-androgen drugs for high risk prostate cancer. The added costs of treating earlier stage disease with all therapies are aligned with their added clinical benefits for patients. For questions or additional information, […]
Intervention of interest: Proton beam therapy ICER completed a Technology Assessment of proton beam therapy (PBT) for the public meeting of the Washington State Health Care Authority Clinical Committee. ICER’s review found that PBT was superior to surgical treatment of tumors of the eye, and appears to be a safer alternative to conventional radiation in […]
Interventions of Interest: Due to the COVID-19 pandemic, we have decided to indefinitely postpone our public meeting on therapies for sickle cell disease (originally slated for March 26, 2020). Please refer to the sickle cell disease evidence report for our most updated findings. Date of review: March 2020 For questions, please contact info@icer.org View the […]
Interventions of Interest: Valbenazine (Ingrezza®, Neurocrine Biosciences, Inc) Deutetrabenazine (Austedo®, Teva) Tetrabenazine (Xenazine®, Ovation Pharmaceuticals) Tardive dyskinesia is a serious and disabling movement disorder that affects individuals treated with antipsychotic agents for a variety of mental health conditions. Though prevention and treatment primarily focus on stopping or changing the offending antipsychotic agent, for some individuals […]
Interventions of Interest: oral semaglutide (Rybelsus®, Novo Nordisk) liraglutide (Victoza®, Novo Nordisk) sitagliptin (Januvia®, Merck) empagliflozin (Jardiance®, Boehringer Ingelheim). Type 2 diabetes mellitus (T2DM) is a condition where cells do not respond adequately to insulin and so there are high glucose (sugar) levels. In the United States approximately 30 million individuals have diabetes mellitus (DM), […]
ICER developed a report assessing the comparative clinical effectiveness and value of voretigene neparvovec (Luxturna®, Spark Therapeutics), a potentially one-time gene therapy for vision loss associated with biallelic RPE65-mediated retinal disease. Voretigene neparvovec is the first gene therapy to be approved by the US Food and Drug Administration (FDA). The appraisal committee vote revealed differences […]
2014 Interventions of Interest: Sulfonylureas Insulin Dipeptidyl peptidase-4 (DPP-4) inhibitors Glucagon-like peptide-1 (GLP-1) receptor agonists Continuous blood glucose monitoring The management of type 2 diabetes has received significant attention over the past decade due to the increasing prevalence of this condition and the rise in costs associated with its treatment. Approximately 29 million Americans have […]
Intervention of interest: Insulin degludec (Tresiba®, Novo Nordisk A/S). The Centers for Disease Control and Prevention (CDC) estimates that 29.1 million Americans have diabetes and 1.7 million adults are newly diagnosed with diabetes mellitus (DM) each year. To treat diabetes, approximately 6 million Americans use insulin therapy as part of their treatment plan to control […]
Interventions of Interest: Emicizumab-kxwh (Hemlibra®, Genentech) Hemophilia A is an inherited condition that results in a deficiency in the factor VIII blood clotting protein. Individuals with hemophilia A are at risk for life-threatening bleeding; bleeding into a joint or muscle is common and can lead to substantial disability. To reduce the risk of bleeding, patients […]
Interventions of interest, May 2015: Devices Temporary intragastric balloon systems (e.g., Silimed®, ReShape®) Vagus nerve block devices (e.g., Maestro® system) Duodenal-jejunal bypass liner (EndoBarrier®) Medications Naltrexone/bupropion sustained-release (Contrave®) Phentermine/topiramate extended-release (Qsymia®) Lorcaserin (Belviq®) Liraglutide (Saxenda®) Intervention of interest, April 2015: Roux-en-Y gastric bypass (RYGB) Biliopancreatic diversion/duodenal switch (BPD/DS) Laparoscopic adjustable gastric banding (LAGB) Vertical sleeve […]